Tri Locum Partners LP Revance Therapeutics, Inc. Transaction History
Tri Locum Partners LP
- $374 Million
- Q3 2024
A detailed history of Tri Locum Partners LP transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Tri Locum Partners LP holds 166,300 shares of RVNC stock, worth $427,391. This represents 1.24% of its overall portfolio holdings.
Number of Shares
166,300Holding current value
$427,391% of portfolio
1.24%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RVNC
# of Institutions
231Shares Held
83.2MCall Options Held
680KPut Options Held
896K-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.73MShares$14.7 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA4.78MShares$12.3 Million0.0% of portfolio
-
Fil LTD Hamilton, D04.19MShares$10.8 Million0.01% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ4.16MShares$10.7 Million0.49% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...